Peter Edman has previously held a number of senior research leadership positions within Pharmacia, Astra and AstraZeneca. He has also held a position as Director and Associate Professor at the Swedish Medical Product Agency. In addition, Peter Edman has comprehensive scientific qualifications from the University of Uppsala, which has rendered him a Ph.D. and an Associate Professor title in biochemistry. Moreover, Peter has been Professor in Pharmaceutical Formulation and Adjunct Professor in Drug Delivery at the Faculty of Pharmacy, Uppsala University.
"Peter Edman will provide significant scientific and leadership capabilities to Biovitrum. He has the right prerequisite skills to transform our long term research focus towards specialist care products. Furthermore Peter's experience in both small molecules and biopharmaceuticals will be a great asset to the company" says Biovitrum's CEO Martin Nicklasson.
"I am really excited about joining Biovitrum. I strongly believe in the new R&D strategy and focused attempts to become a strong international player within specialist care pharmaceuticals and I can see the company's opportunities in both small molecules and biopharmaceuticals." says Peter Edman.
Peter Edman will assume his position during the second quarter 2008.
For more information, please contact: Martin Nicklasson, CEO Phone: +46 8 697 20 00 martin.nicklasson@biovitrum.com
About Biovitrum
Biovitrum is a pharmaceutical company with operations in Sweden and in the UK. Biovitrum has currently a research portfolio with several projects in clinical and preclinical phases for a number of well defined specialist indications as well as for common diseases within obesity, diabetes, inflammation, eye and blood diseases. Biovitrum develops and produces protein-based drugs on a contractual basis and markets a range of specialist pharmaceuticals primarily in the Nordic countries. Biovitrum has revenues of approximately SEK 1.2 billion and around 500 employees. Biovitrum's share is listed on the OMX Nordic Exchange in Stockholm since September 15, 2006. For more information see www.biovitrum.com.
